Philipp Kapp

Philipp Kapp

Auto-generated profile, based on publicly available information

Philipp Kapp

Institute for Evidence in Medicine; Medical Center – University of Freiburg / Medical Faculty – University of Freiburg; Freiburg Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2019 in Nutrition Reviews
Verified
Journal Article
Closed access
DGDaniela Küllenberg de Gaudry
Daniela Küllenberg de Gaudry
SLSzimonetta Lohner
Szimonetta Lohner
CSChristine Schmucker
Christine Schmucker
PKPhilipp Kapp
Philipp Kapp
EMEdith Motschall
Edith Motschall
JMJörg J Meerpohl
Jörg J Meerpohl
Various epidemiological studies suggest a positive association between exposure to cow's milk A1 β-casein protein and risk for noncommunicable chronic diseases. The consumption of A2 cow's milk is increasing, likely because A2 milk is postulated to have positive effects on digestive health. A systematic review was conducted to investigate associations between A1 β-casein and health-related outcomes in humans. Five electronic databases, 3 clinical trial registries, and the internet were searched systematically. Using predefined inclusion criteria, 2 authors independently selected studies investigating the effect of A1 β-casein or β-casomorphin-7 intake/exposure on any health-related outcome in humans. Discrepancies were resolved by consensus. Two authors independently extracted data and assessed risk of bias. The certainty of evidence per outcome was evaluated using the GRADE approach. Discrepancies were resolved by consensus. Fifteen randomized controlled trials, 2 case-control studies, and 8 ecological studies were included. Most randomized controlled studies and case-control studies investigating a potential effect on various outcomes were based on intermediate markers and found no significant difference between the 2 milk types. In contrast, most ecological studies reported that population-level A1 β-casein exposure is associated with adverse health outcomes. The certainty of the evidence for the included outcomes, as assessed by the GRADE approach, was rated as moderate for digestive symptoms and as low to very low for all other outcomes. Human-based evidence from clinical trials and epidemiological studies published prior to October 2017 provides moderate certainty for adverse digestive health effects of A1 β-casein compared with A2 β-casein but low or very low certainty for other health effects. These conclusions may change in the future, given the emergent nature of this topic and the ongoing research in this area. PROSPERO registration number CRD42016043795.

9 February 2019 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Open access
PDF file
JLJan Löhler
Jan Löhler
LWLeif Erik Walther
Leif Erik Walther
FHFynn Hansen
Fynn Hansen
PKPhilipp Kapp
Philipp Kapp
JMJörg Meerpohl
Jörg Meerpohl
CSChristine Schmucker
Christine Schmucker
Background Worldwide approximately 360 million people suffer from hearing impairment, 328 million of whom are adults. Up to now there has been no systematic evaluation of any representative epidemiological data on the prevalence of hearing loss among adults in Germany. The present paper is intended to investigate this within the framework of a systematic review. Methods A systematic literature search was carried out in electronic databases as well as by means of hand-searching. Studies published after 1975 and indicating the prevalence or incidence of hearing impairment among German adults were included. Study selection, data extraction and additional quality assessments were made by two independent reviewers. Results By means of a systematic literature search it was possible to identify 6 sources, which provided solely cross-sectional data, whereby the reported data are based on a study population of between some hundred and 10 million people living in Germany. The prevalences ascertained showed a broad range of between 16% and 25% and varied according to age, study setting, definition of hearing loss and method of data capture. At present there are no utilizable data on the extent of the use of hearing aids. Discussion The present review demonstrates clearly that evidence-based information relating to Germany can only be made on the basis of a clear definition of hearing loss within the framework of an up-to-date and representative epidemiological study carried out with appropriate methodology. In view of the high prevalence of illnesses causing hearing impairment and of the risks to health associated with untreated hearing impairment as well as of socio-economic costs, such an epidemiological study is of great social significance.

18 September 2019 in BMC Public Health
Verified
Journal Article
Open access
PDF file
CSChristine Schmucker
Christine Schmucker
PKP. Kapp
P. Kapp
EME. Motschall
E. Motschall
JLJ. Loehler
J. Loehler
JMJ. J. Meerpohl
J. J. Meerpohl
Background: Current data suggest that approximately 466 million people (5.0%) of the world’s population have disabling hearing loss, therefrom, 34 million children, impacting their quality of life. To provide estimates on the prevalence of hearing loss on a national level, we reviewed the epidemiological literature addressing hearing loss in children and adolescents living in Germany as an example for a Western country. Methods: We searched Medline, Web of Science, Cochrane Library, ScienceDirect and LIVIVO to identify published data. Furthermore, we manually searched websites of relevant institutions and journals not listed in electronically and searched for ongoing studies and/or not yet published data in clinicaltrials.gov. Study selection, data extraction, and methodological assessment were carried out by two reviewers. Results: In total, 11 reports provided data with sample sizes ranging from 310 up to more than 14 million children and adolescents. Prevalence data were collected by interviews (self-assessments), using pure-tone audiometry or the international classification of diseases (ICD-10) coding and ranged from 0.1 to 128 per 1000 children. Although the estimate of the prevalence of hearing loss goes down, when the threshold was raised, generating a comprehensive and coherent set of estimates proved challenging owing to clinical heterogeneity including variation in age, the study setting, the definition of hearing loss and the assessment method. Moreover, representativeness (external validity) was often impaired owing to estimates lacking currentness (i.e., referring to former West Germany) or selected (patient) data and may not be typical for a more general population. Conclusions: In conclusions, this work raises public awareness of the high prevalence of hearing loss, highlights issues associated with epidemiological research and is of great importance for researcher and those who use epidemiological data to inform clinical and political decision making.

8 September 2025 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
PKPhilipp Kapp
Philipp Kapp
CSChristine Schmucker
Christine Schmucker
WSWaldemar Siemens
Waldemar Siemens
TBTimo Brugger
Timo Brugger
LGLea Gorenflo
Lea Gorenflo
JMJoerg J Meerpohl
Joerg J Meerpohl

11 April 2026 in eClinicalMedicine
Verified
Journal Article
Open access
PKPhilipp Kapp
Philipp Kapp
WSWaldemar Siemens
Waldemar Siemens
LGLea Gorenflo
Lea Gorenflo
HSHenriette Schulz
Henriette Schulz
YCYuan Chi
Yuan Chi
JMJoerg J. Meerpohl
Joerg J. Meerpohl
Immunocompromised individuals may be at an increased risk for human papillomavirus (HPV)-related diseases and cancers, but the protective benefit of HPV vaccination remains unclear. In this systematic review and meta-analysis we assessed the efficacy, effectiveness, immunogenicity, and safety of HPV vaccination in non-HIV immunocompromised individuals. We searched MEDLINE, Embase and CENTRAL (26 November 2025) for randomised and non-randomised studies comparing vaccinated immunocompromised individuals to unvaccinated immunocompromised individuals (comparison 1). Additionally, we considered studies comparing vaccinated immunocompromised individuals to vaccinated individuals with a different disease or condition (comparison 2) or vaccinated healthy individuals (comparison 3). We assessed the risk of bias (ROBINS-I) and the certainty of evidence (CoE; GRADE) for prioritised outcomes including cervical precancer or cancer, HPV types 16 and 18 immunogenicity, and serious adverse events. We pooled studies using the random-effect meta-analyses model. This study is registered in PROSPERO, CRD42024554574. We identified 24 non-randomised studies, comprising various immunocompromised populations (e.g. solid organ transplant recipients or autoimmune diseases). One case–control study compared vaccinated immunocompromised with unvaccinated immunocompromised individuals (comparison 1), reporting rate ratios near the null effect for effectiveness against cervical intraepithelial neoplasia (CIN) 2+ (0.96, 95% CI 0.68–1.37) and CIN 3+ (0.96, 95% CI 0.54–1.70), although the CoE was very low. Most studies assessed immunogenicity, generally showing high seropositivity rates (median at 7 months 95.8%, IQR 89.2–99.7; 13 studies) in immunocompromised individuals compared to other immunocompromised or healthy individuals, with a CoE ranging from low to very low (comparisons 2 and 3). Antibody titres were generally high but varied across immunocompromised populations. Serious adverse events were rare and deemed unrelated to vaccination. HPV vaccination appears immunogenic and safe for non-HIV immunocompromised individuals, but the CoE is low to very low and heterogeneity across populations limits generalisability of the findings and pooled analyses. Given the unclear correlate of protection and lack of standardisation of assays for antibody measurement, immunogenicity data should be interpreted cautiously. Future studies should assess HPV-associated precancerous lesions and cancers, and explore subgroups effects, including differences in sex, age, immunosuppressive treatments, and dosing. 10.13039/100032850 EU4Health Programme - European Health and Digital Executive Agency, European Commission. Service Contract HaDEA/OP/2021/0011.

4 February 2022 in medRxiv
Verified
Preprint
Open access
PDF file
PKPhilipp Kapp
Philipp Kapp
LELaura Esmail
Laura Esmail
LGLina Ghosn
Lina Ghosn
PRPhilippe Ravaud
Philippe Ravaud
IBIsabelle Boutron
Isabelle Boutron
Randomized controlled trials (RCTs) are essential to support clinical decision making. We assessed the transparency, completeness and consistency of reporting of 244 reports (120 peer-reviewed journal publications; 124 preprints) of RCTs assessing pharmacological interventions for the treatment of COVID-19 published the first 17 months of the pandemic (up to May 31, 2021). Transparency was poor. Only 55% of trials were prospectively registered; 39% made their full protocols available and 29% provided access to their statistical analysis plan. Only 6% completely reported the most important information. Primary outcome(s) reported in trial registries and published reports were inconsistent in 47% of trials. Of the 124 RCTs published as preprint, 76 were secondarily published in a peer-reviewed journal. There was no major improvement after the peer-review process. Lack of transparency, completeness and consistency of reporting is an important barrier to trust, interpretation and synthesis in COVID-19 clinical trials.